AML

Priothera begins subject enrolment in AML therapy trial
Clinical Trials Arena
Mon, 01/23/23 - 09:50 pm
Priothera
AML
mocravimod
Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact
Fierce Biotech
Mon, 01/9/23 - 10:39 am
Kronos Bio
biobucks
AML
Roche
Genentech
small molecule drugs
drug discovery
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Pulse 2.0
Wed, 12/21/22 - 11:27 am
Magenta Therapeutics
clinical trials
MGTA-117
AML
myelodysplastic syndrome
Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML
Xtalks
Wed, 12/7/22 - 09:53 am
Rigel Pharmaceuticals
Rezlidhia
olutasidenib
FDA
AML
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
Fierce Biotech
Thu, 11/10/22 - 10:39 am
Cyclacel
AML
Sapacitabine
Daiichi Sankyo
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
BioSpace
Tue, 08/23/22 - 10:35 am
Foghorn Therapeutics
FHD-286
AML
MDS
FDA
clinical trials
FDA grants fast track designation for Priothera’s AML therapy
Pharmaceutical Business Review
Tue, 05/31/22 - 10:45 am
Priothera
mocravimod
stem cells
AML
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
Benzinga
Fri, 05/20/22 - 10:28 am
Foghorn Therapeutics
clinical trials
FDA
FHD-286
acute myelogenous leukemia
AML
patient death
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
Fierce Biotech
Wed, 02/2/22 - 12:15 pm
Gilead Sciences
clinical trials
clinical hold
magrolimab
AML
MDS
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
Fierce Biotech
Mon, 01/24/22 - 10:14 am
MaaT Pharma
microbiome
clinical trials
AML
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
Fierce Pharma
Sat, 12/11/21 - 09:15 pm
ASH2021
Servier
Tibsovo
AML
ASH: Senti Bio's gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models
Fierce Biotech
Thu, 12/9/21 - 11:00 am
Senti Biosciences
natural killer cells
AML
CAR-NK
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
Wed, 11/24/21 - 10:23 am
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
BioSpace
Wed, 11/24/21 - 10:14 am
Kura Oncology
KOMET-001
KO-539
AML
patient deaths
Aptevo Soars on Reports of Complete Remission in AML
BioSpace
Tue, 11/23/21 - 08:56 pm
Aptevo
clinical trials
AML
APVO436
bispecifics
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Fierce Biotech
Tue, 11/23/21 - 09:47 am
Rafael Pharmaceuticals
devimistat
clinical trials
pancreatic cancer
AML
reorganization
Daiichi could be rewarded for persisting with Vanflyta
EP Vantage
Fri, 11/19/21 - 10:49 am
Daiichi Sankyo
Vanflyta
AML
FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test
Fierce Biotech
Wed, 10/20/21 - 06:54 pm
AstraZeneca
clinical trials
FDA
clinical hold
AZD5991
AML
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Pharmaforum
Mon, 08/2/21 - 09:39 pm
Servier
Agios
M&A
Tibsovo
AML
Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug
BioSpace
Wed, 07/21/21 - 08:41 pm
Magenta Therapeutics
AML
MDS
FDA
clinical hold
MGTA-117

Pages